DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer

Decoy technology is a versatile and specific DNA oligonucleotide-based targeting strategy of pathogenic transcription factors (TFs). Chemical modifications of linear decoy oligonucleotides have been made to decrease nuclease sensitivity because of the presence of free ends but at the cost of new lim...

Full description

Saved in:
Bibliographic Details
Main Authors: Geoffrey Casas (Author), Federico Perche (Author), Patrick Midoux (Author), Chantal Pichon (Author), Jean-Marc Malinge (Author)
Format: Book
Published: Elsevier, 2022-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_25ce9cf87b3848e2b18fbde3bedfc7f2
042 |a dc 
100 1 0 |a Geoffrey Casas  |e author 
700 1 0 |a Federico Perche  |e author 
700 1 0 |a Patrick Midoux  |e author 
700 1 0 |a Chantal Pichon  |e author 
700 1 0 |a Jean-Marc Malinge  |e author 
245 0 0 |a DNA minicircles as novel STAT3 decoy oligodeoxynucleotides endowed with anticancer activity in triple-negative breast cancer 
260 |b Elsevier,   |c 2022-09-01T00:00:00Z. 
500 |a 2162-2531 
500 |a 10.1016/j.omtn.2022.06.012 
520 |a Decoy technology is a versatile and specific DNA oligonucleotide-based targeting strategy of pathogenic transcription factors (TFs). Chemical modifications of linear decoy oligonucleotides have been made to decrease nuclease sensitivity because of the presence of free ends but at the cost of new limitations that affect their use as therapeutic drugs. Although a short DNA minicircle is a phosphodiester nucleic acid without free ends, its potential therapeutic activity as a TF decoy oligonucleotide has not yet been investigated. Here we describe the in vitro and in vivo activity of formulated 95-bp minicircles bearing one or several STAT3 binding sequences in triple-negative breast cancer (TNBC). Minicircles bearing one STAT3 binding site interacted specifically with the active form of STAT3 and inhibited proliferation, induced apoptosis, slowed down cell cycle progression, and decreased STAT3 target gene expression in human and murine TNBC cells. Intratumoral injection of STAT3 minicircles inhibited tumor growth and metastasis in a murine model of TNBC. Increasing the number of STAT3 binding sites resulted in improved anticancer activity, opening the way for a TF multitargeting strategy. Our data provide the first demonstration of minicircles acting as STAT3 decoys and show that they could be an effective therapeutic drug for TNBC treatment. 
546 |a EN 
690 |a MT: Oligonucleotides: Therapies and Applications 
690 |a DNA minicircle 
690 |a therapeutic oligonucleotide 
690 |a decoy 
690 |a transcription factor 
690 |a STAT3 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Molecular Therapy: Nucleic Acids, Vol 29, Iss , Pp 162-175 (2022) 
787 0 |n http://www.sciencedirect.com/science/article/pii/S2162253122001640 
787 0 |n https://doaj.org/toc/2162-2531 
856 4 1 |u https://doaj.org/article/25ce9cf87b3848e2b18fbde3bedfc7f2  |z Connect to this object online.